Netrin-1: a new player in multiple sclerosis pathogenesis?

Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/158177

COMPARTIR / EXPORTAR:

SHARE BASE	Comparte tu historia de Acceso Abierto
Visualizar otros formatos: MARC \| Dublin Core \| RDF \| ORE \| MODS \| METS \| DIDL \| DATACITE
Refman EndNote Bibtex RefWorks Excel CSV PDF DataCite Send via email

Campo DC	Valor	Lengua/Idioma
dc.contributor.author	Mulero, Patricia	-
dc.contributor.author	Cordova, Claudia	-
dc.contributor.author	Gutiérrez, Beatriz	-
dc.contributor.author	Martín, Rubén	-
dc.contributor.author	Hernández, Marita	-
dc.contributor.author	Muñoz, Juan Carlos	-
dc.contributor.author	Nieto, María Luisa	-
dc.contributor.author	Téllez, Nieves	-
dc.date.accessioned	2017-12-14T10:19:58Z	-
dc.date.available	2017-12-14T10:19:58Z	-
dc.date.issued	2015	-
dc.identifier.citation	ECTRIMS (2015)	-
dc.identifier.uri	http://hdl.handle.net/10261/158177	-
dc.description	Resumen del póster presentado al 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, celebrado en barcelona (España) del 7 al 10 de octubre de 2015.-- et al.	-
dc.description.abstract	[Background]: Netrin-1 is a secreted protein that regulates axon guidance and glial cell migration. In the experimental autoimmune encephalomyelitis (EAE) model, several reports indicate that netrin-1 reduces the levels of pro-inflammatory mediators in the blood and that stabilizes the blood¿brain barrier limiting the entrance of the immune cells from the periphery to the central nervous system Tough these observations could suggest an involvement of Netrine-1 in the Multiple Sclerosis (MS) pathogenesis, the behaviour of this molecule have never been demonstrated in humans. [Objective]: to determinate serum levels of netrin-1 in a cohort of MS patients and compare it with a control group (CG). Secondly, to study the relationship between serum netrin-1 levels with clinical inflammatory activity. [Methods]: a total of 100 MS patients (%female: 63; Age, mean±SD: 42±11.5) (%Clinically Isolated Syndrome (CIS): 6; %Relapsing-Remitting MS (RRMS): 58; %Primary-Progressive MS (PPMS): 13; %Secondary Progressive MS (SPMS): 23) and 50 GC (%female: 46; Age, mean±SD: 57±11.3) were included. Ten RRMS patients were evaluated during a relapse of the disease (RRMSr) and longitudinally 2 months later. Netrin-1 levels were measured in serum samples using a quantitative ELISA kit from Cusabio Biotech (Wuhan, China), according to the manufacturer¿s instructions. The minimal limit of detection was 7.81 pg/ml. [Results]: MS patients showed statistically significant lower netrin-1 levels compared to CG (MS (mean±SD): 511.62±209.30; CG: 748.32±103.24) (p<0.005). Remarkably, this difference was more pronounced in RRMSr who showed the lowest protein level (304.4±107.07) that remaining significantly decreased two months later. We did not found statistically significant differences in MS netrine-1 levels according to age (p=0.15), gender (p=0.07), disease subtype (p=0.63), MS onset (p=0.27), Expanded Disability Status Scale (p=0.65), Multiple Sclerosis Severity Score (p=0.23), immunomodulatory therapies (p=0.07) or relapses number in last two years (p=0.57). [Conclusion]: Our data showed that serum netrin-1 levels are decreased in MS patients, particularly during a relapse of the disease. This would be in agreement with previous reports in EAE models suggesting an anti-inflammatory effect of the netrin-1 in MS.	-
dc.rights	closedAccess	-
dc.title	Netrin-1: a new player in multiple sclerosis pathogenesis?	-
dc.type	póster de congreso	-
dc.date.updated	2017-12-14T10:19:58Z	-
dc.description.version	Peer Reviewed	-
dc.language.rfc3066	eng	-
dc.relation.csic	Sí	-
dc.type.coar	http://purl.org/coar/resource_type/c_6670	es_ES
item.fulltext	No Fulltext	-
item.openairecristype	http://purl.org/coar/resource_type/c_18cf	-
item.openairetype	póster de congreso	-
item.cerifentitytype	Publications	-
item.grantfulltext	none	-
Aparece en las colecciones:	(IBGM) Comunicaciones congresos